-
Loading metrics
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
-
Deborah Charych ,
Contributed equally to this work with: Deborah Charych, Samira Khalili
Roles Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: DCharych@nektar.com
Affiliation Nektar Therapeutics, San Francisco, California, United States of America
⨯ - Samira Khalili ,
- Vidula Dixit,
- Peter Kirk,
- Thomas Chang,
- John Langowski,
- Werner Rubas,
- Stephen K. Doberstein,
- Michael Eldon,
- Ute Hoch,
- Jonathan Zalevsky
http://orcid.org/0000-0002-1293-0366
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
- Deborah Charych,
- Samira Khalili,
- Vidula Dixit,
- Peter Kirk,
- Thomas Chang,
- John Langowski,
- Werner Rubas,
- Stephen K. Doberstein,
- Michael Eldon,
- Ute Hoch
x
- Published: July 5, 2017
- https://doi.org/10.1371/journal.pone.0179431